Abstracts tagged "Heart disease"

Abstract Number: 1596 • ACR Convergence 2022
The Role of Coronary Calcium Screening in Patients with Lupus Who Appear to Be at Low Cardiovascular Risk
Sarah Stoots¹, Joshua Baker¹ and Joan Von Feldt², ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Wilmington, DE
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) are at elevated cardiovascular risk. However, common risk calculators such as the atherosclerotic cardiovascular disease (ASCVD) risk estimator…
Abstract Number: 0679 • ACR Convergence 2022
Outcomes of Antiphospholipid Antibody Syndrome and Acute Coronary Syndrome: Analysis of National Inpatient Sample 
Faria Sami, Dennis Kumi and Shilpa Arora, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Antiphospholipid antibody syndrome (APLS) is strongly associated with the risk of cardiovascular events including acute coronary syndrome (ACS). However, there is limited data on…
Abstract Number: 1623 • ACR Convergence 2022
Combined Single-Cell, Bulk RNA Sequencing and Proteomics Analysis Reveals New Candidate Targets Involved in Myocardial Fibrogenesis
Ievgeniia Kocherova¹, Elena Pachera², Daria Nurzynska³, Franca Di Meglio³, Oliver Distler⁴, Przemysław Błyszczuk² and Gabriela Kania², ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ³Department of Public Health, University of Naples "Federico II", Naples, Italy, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Inflammatory dilated cardiomyopathy (iDCM) often leads to heart failure (HF), which is the main cause of cardiac mortality in patients with systemic autoimmune diseases.…
Abstract Number: 0741 • ACR Convergence 2022
Prescribing Patterns of SGLT2 Inhibitors for Patients with Autoimmune Rheumatic Disease
Emily G Oakes¹, Jack Ellrodt¹, May Choi², Hongshu Guan¹ and Karen Costenbader¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i, dapagliflozin, canagliflozin, and empagliflozin) are a class of oral hypoglycemic medication for management of Type II diabetes mellitus (T2D),…
Abstract Number: 1789 • ACR Convergence 2022
Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital
Aakriti Arora¹, Lakshmi Jayaram², TEFERA ESHETU³ and FLORINA CONSTANTINESCU³, ¹MedStar Washington Hospital Center, Georgetown University, Washington, DC, ²McGaw Medical Center, Northwestern University, Chicago, IL, ³MedStar Washington Hospital Center, Washington, DC
Background/Purpose: Gout is one of the most common inflammatory joint diseases and is a disabling complication in patients with heart failure. Patients with gout and…
Abstract Number: 0805 • ACR Convergence 2022
Rheumatic Fever and Streptococcal Cutaneous Infection: A Case-control Study in the Loyalty Islands, New Caledonia
Quentin AMIC-DESVAUD¹, Olivier MAILLARD², Sylvia IACOBELLI³, Thomas BARDIN⁴ and Yves-Marie DUCROT⁵, ¹Province des îles Loyauté, Lifou, New Caledonia, ²Centre Hospitalier Universitaire de la Reunion, Saint-Denis, France, ³Centre Hospitalier Universitaire, Saint Dénis de la Réunion, France, ⁴Université de Paris, Paris, France, ⁵Province des îles Loyauté, We, Lifou Island, New Caledonia
Background/Purpose: Acute Rheumatic Fever (ARF) and Rheumatic Heart Disease (RHD) remain major public health problems in the South Pacific. Triggering by group A beta hemolytic…
Abstract Number: 1815 • ACR Convergence 2022
Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
Gary Ho¹, Michael Toprover², Daria Crittenden³, binita Shah⁴ and Michael Pillinger⁵, ¹New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ²Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, ³CymaBay Therapeutics, New York University Grossman School of Medicine, Newark, CA, ⁴New York University Grossman School of Medicine, VA New York Harbor Health Care System, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced…
Abstract Number: 0272 • ACR Convergence 2021
RA Disease Activity Is an Independent Predictor of Left Ventricular Mass Changes in an RA Cohort Without Cardiovascular Disease
Elizabeth Park¹, Kazato Ito¹, Christopher Depender¹, Jon Giles¹ and Joan Bathon², ¹Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ²Columbia University, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) patients have 50% increased risk of heart failure (HF) vs non-RA patients with a distinct phenotype, preserved ejection fraction on transthoracic…
Abstract Number: 0283 • ACR Convergence 2021
Cardiovascular Risk Management in Patients with Rheumatoid Arthritis: A Single-centered Cross-sectional Study
SAMAR ABOULENAIN¹, Khaled Deeb², Mohamed Abdul Qader¹ and Can Jones¹, ¹University of Miami Miller School, West Palm Beach, FL, ²West Palm Beach VA Medical Center, West Palm Beach, FL
Background/Purpose: Cardiovascular (CV) disease is the leading cause of death in patients with rheumatoid arthritis (RA) and is estimated to be responsible for 29%-32% of…
Abstract Number: 0405 • ACR Convergence 2021
Retrospective Study on the Prognostic Value of Cardiac Magnetic Resonance Imaging Abnormalities in Systemic Sclerosis
Hao Cheng Shen¹, Catherine Faucher², Anne Chin³, Carl Chartrand-Lefebvre³, Ragui Chehata⁴, Julia Cadrin-Tourigny⁵, Francois-Pierre Mongeon⁶, Jean-Paul Makhzoum⁷, Océane Landon-Cardinal⁸, Josiane Bourré-Tessier⁸, Éric Rich⁹, Jean-Richard Goulet⁸, Paul R Fortin¹⁰, Jean-Luc Senécal⁸ and Sabrina Hoa⁸, ¹Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Department of Medicine, Université Laval, Québec, QC, Canada, ³Department of Radiology, Centre hospitalier de l’Université de Montréal, Montréal, QC, Canada, ⁴Department of Medicine, Université de Montréal, Montreal, Montréal, QC, Canada, ⁵Division of Non-Invasive Cardiology, Department of Specialized Medicine, Montreal Heart Institute; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁶Division of electrophysiology, Department of Specialized Medicine, Montreal Heart Institute; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁷Division of Internal Medicine, Hôpital Sacré-Coeur de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁸Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁹Division of Rheumatology, Centre hospitalier de l’Université de Québec-Université Laval, Montréal, QC, Canada, ¹⁰CHU de Quebec - Universite Laval, Québec City, QC, Canada
Background/Purpose: Cardiac involvement is a leading cause of death in systemic sclerosis (SSc). Cardiac MRI (CMR) is useful in the early assessment of cardiac disease.…
Abstract Number: 0516 • ACR Convergence 2021
Dual Fibroblast Transdifferentiation Mediated by Type I Interferon: Application to Anti-Ro Mediated Congenital Heart Block
Christina Firl¹, Miao Chang², Jill Buyon³ and Robert Clancy¹, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Langone Health, New York, NY, ³NYU School of Medicine, New York, NY
Background/Purpose: Linking inflammation to fibrosis, a common end stage feature of many autoantibody mediated rheumatic diseases, remains a challenge. Indeed the signature hallmark of anti-Ro…
Abstract Number: 0645 • ACR Convergence 2021
Time Burden of QTc Screening for HCQ Users at a Single VA Rheumatology Clinic
Iziegbe Ehiorobo¹, Anna Montgomery² and Gabriela Schmajuk¹, ¹University of California San Francisco, San Francisco, CA, ²Department of Veterans Affairs, Tiburon, CA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in the treatment of rheumatic diseases. New guidance from the ACR supports routine monitoring of the QT…
Abstract Number: 1464 • ACR Convergence 2021
Ambulatory Fetal Heart Rate Monitoring (FHRM) to Surveil Pregnancies at Risk for Congenital Heart Block
Mala Masson¹, Colin Phoon¹, Elena Sinkovskaya², Lisa Howley³, Ruben Acherman⁴, Majd Makhoul⁵, Nelangi Pinto⁶, Miao Chang¹, Robert Clancy⁷, Bailey Drewes⁸, Bettina Cuneo⁹ and Jill Buyon⁷, ¹NYU Langone Health, New York, NY, ²East Virginia Medical School, Norfolk, ³Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, ⁴Sunrise Children's Hospital, Las Vegas, NV, ⁵UK Kentucky Children's Hospital, Lexington, KY, ⁶University of Utah, Salt Lake City, UT, ⁷NYU Grossman School of Medicine, New York, NY, ⁸CU Anschutz Medical Campus, Aurora, ⁹Children's Hospital Colorado, Aurora, CO
Background/Purpose: Congenital Heart Block (CHB) complicates 2% of anti-Ro/SSA antibody positive pregnancies and carries substantial perinatal morbidity and mortality. Almost all survivors require lifelong pacing.…
Abstract Number: 1925 • ACR Convergence 2021
Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study
Sahil Koppikar¹, Bindee Kuriya², Jacob Udell³, Bing Yu⁴, Anna Chu⁴, Laura Ferreira-Legere⁵, Douglas Lee³, Jessica Widdifield⁶ and Lihi Eder³, ¹Women's College Hospital, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴ICES, Toronto, ON, Canada, ⁵ICES, Toronto, Canada, ⁶Sunnybrook Research Institute; ICES; Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Individuals with inflammatory diseases (ID) have an increased risk of cardiovascular disease, frequently compared to that of diabetes mellitus (DM). However, the magnitude of…
Abstract Number: 1189 • ACR Convergence 2020
Serum High-sensitive Cardiac Troponin at Baseline Predict Cardiovascular Events in Rheumatoid Arthritis and Osteoarthritis
M. Elaine Husni¹, Daniel H Solomon², Mingyuan Shao³, Katherine Wolski³, Steven Nissen³, Stanley Hazen⁴ and WH Wilson Tang⁴, ¹Cleveland Clinic, Cleveland, OH, ²Brigham and Women's Hospital, Boston, MA, ³Cleveland Clinic Foundation, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland
Background/Purpose: In rheumatoid arthritis (RA), excess mortality and inflammation has been attributed to cardiovascular (CV) diseases. High-sensitivity cardiac troponins (hscTnT) allow measurement of cardiac troponin…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.